Medicines bill under control in the UK
Time is right for universal health coverage
Scramble to fix the new US health insurance exchange website
Changes to England's NHS spending likely mean cuts
Concern over access to new anticancer drugs in Quebec
England's NHS a national, not an international, health service
Statins not worth it for pts at low risk of CVD
Generics − no perfect solution
Asthma drug pricing a problem for many countries
Proton RT good value for money in paediatric medulloblastoma
Coping intervention for family carers − a cost-effective START
Cyclophosphamide + azathioprine best option for LN in Thailand
Multidisciplinary team meetings in oncology costly
Telehealth does not increase GP workload
Cost a barrier for self-paid vaccination in Poland
Newer HIV drugs cost effective?
RCT data not to be RE-LYed on, 'real-world' NOAC users older
Eliminating cost-sharing improves medication adherence after CABG
Finding cost-effective options for resistant depression
Measles outbreaks burden on US public health departments
TKR cost effective in patients with end-stage osteoarthritis
Rheumatoid arthritis costs rise in Sweden
CBT promising for health anxiety in medical patients in the UK
Medicare prostate screening costs: substantial and variable
Peginterferon-α-2a better option for hepatitis C in Brazil
No change in cost of stroke care in Canada over 10 years
PRA-driven use of P2Y12 inhibitors the way to go in ACS
Selecting optimal FPG threshold to identify high T2DM risk
Prescription drug use in Medicare patients varies widely across US
Societal costs of cancer in the EU over euro120 billion
Reimbursement changes for ARBs brings cost savings in Denmark
Ireland's 2014 health budget announced
The Australian government has allocated $A1.4 million to fund insulin pumps for children with type 1 diabetes mellitus (T1DM).
T2DM market to double in next decade
NHS England has dropped the Specialised Services Commissioning Innovation Fund (SSCIF) − the fund dedicated to rare health conditions and diseases.
NICE 'yes' for ocriplasmin and enzalutamide